Personalized and Precision Oncology (PPO) via Cancer Pathology related Modeling and IT-Assisted Clinical Practice to Prevent, to Treat and to Get Cured Cancer and Its Complications: A Role of Precision Cancer Pathology in the Era of PPO

Authors

  • Sergey Suchkov N.D. Zelinskii Institute for Organic Chemistry, Moscow, Russia, National Cen-ter for Human Photosynthesis, Aguascalientes, México, EPMA, Brussels, EU, PMC, Washington, DC, USA, ISPM, Tokyo, Japan, ACS, Washington, DC, USA, InMedStar, Russia-UAE, Russian Academy of Natural Sciences, Moscow. Author
  • William Thilly MIT, Cambridge, MA, USA. Author
  • Shawn Murphy MGH and 8Harvard Medical School, Boston, MA, USA. Author
  • David Smith Center for Cancer Genomics, Mayo Clinic, Rochester, MN, USA. Author
  • Hiroyuki Abe ISPM, Tokyo, Japan, Abe Cancer Clinic, Tokyo, Japan. Author
  • Michael Joe Duffy UCD School of Medicine and Conway Institute of Biomolecular and Biomedical Research, University College Dublin and Center for Cancer Pathology, St Vincent’s University Hospital, Dublin, Ireland. Author
  • R Holland Cheng College of Biological Sciences, University of California Davis, Davis, CA, USA. Author

DOI:

https://doi.org/10.47363/JCRR/2025(7)210

Keywords:

Precision Oncology, Cancer Pathology, Get Cured Cancer, PPO

Abstract

A new systems approach to diseased states and wellness result in a new branch in the healthcare services, namely, Personalized and Precision Medicine (PPM). To achieve the implementation of PPM concept, it is necessary to create a fundamentally new strategy based upon the recogni-tion of biomarkers and thus the targets to secure the grand future of drug design and drug dis-covery. Each decision-maker values the impact of their decision to use PPM on their own budget and well-being, which may not necessarily be optimal for society as a whole. It would be extremely useful to integrate data harvesting from different databanks for applications to provide more tai-lored measures for the patients resulting in improved patient outcomes, reduced adverse events, and more cost-effective use of the latest health care resources including diagnostic (companion ones or theranostics), preventive and therapeutic (targeted molecular and cellular) etc.

Meanwhile, along with the impact of genomics and bioinformatics, pathology is the central specialty of PPM-related resources. Coupled with IT, the upgraded tools are ever more efficient and robust within clinical cancer settings. The latest algorithms may be able to identify and vali-date patterns which humans are not capable of quantifying easily, such as slight differences in textures or morphologies. In this sense, the impact of pathology allows a modular approach, as its various aspects are under development in several areas of PPM.

Among the above-mentioned medical specialists involved in PPM, the pathologists play an im-portant and key role in the implementation and development of PPM-driven resources that are in the center of decision of many therapeutic choices. Recent advances in systems biology have tremendously affected the practice of precision pathology, gradually transforming it from a morphology-based into a precise molecular-based discipline.

Author Biographies

  • Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry, Moscow, Russia, National Cen-ter for Human Photosynthesis, Aguascalientes, México, EPMA, Brussels, EU, PMC, Washington, DC, USA, ISPM, Tokyo, Japan, ACS, Washington, DC, USA, InMedStar, Russia-UAE, Russian Academy of Natural Sciences, Moscow.

    Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry, Moscow, Russia, National Cen-ter for Human Photosynthesis, Aguascalientes, México, EPMA, Brussels, EU, PMC, Washington, DC, USA, ISPM, Tokyo, Japan, ACS, Washington, DC, USA, InMedStar, Russia-UAE, Russian Academy of Natural Sciences, Moscow.

  • William Thilly, MIT, Cambridge, MA, USA.

     William Thilly, MIT, Cambridge, MA, USA.

  • Shawn Murphy, MGH and 8Harvard Medical School, Boston, MA, USA.

    Shawn Murphy, MGH and 8Harvard Medical School, Boston, MA, USA.

  • David Smith, Center for Cancer Genomics, Mayo Clinic, Rochester, MN, USA.

    David Smith, Center for Cancer Genomics, Mayo Clinic, Rochester, MN, USA.

  • Hiroyuki Abe, ISPM, Tokyo, Japan, Abe Cancer Clinic, Tokyo, Japan.

    Hiroyuki Abe, ISPM, Tokyo, Japan, Abe Cancer Clinic, Tokyo, Japan.

  • Michael Joe Duffy, UCD School of Medicine and Conway Institute of Biomolecular and Biomedical Research, University College Dublin and Center for Cancer Pathology, St Vincent’s University Hospital, Dublin, Ireland.

    Michael Joe Duffy, UCD School of Medicine and Conway Institute of Biomolecular and Biomedical Research, University College Dublin and Center for Cancer Pathology, St Vincent’s University Hospital, Dublin, Ireland.

  • R Holland Cheng, College of Biological Sciences, University of California Davis, Davis, CA, USA.

    R Holland Cheng, College of Biological Sciences, University of California Davis, Davis, CA, USA.

Downloads

Published

2025-03-31

Issue

Vol. 7 No. 2 (2025): Volume 7 Issue 2

Section

Articles